In the advanced disease setting, the CLEOPATRA trial demonstrated superior overall survival (OS) and progression-free survival (PFS) after adding pertuzumab to trastuzumab and docetaxel in patients with HER2+ metastatic BC naïve to anti-HER2 therapy and chemotherapy for metastatic disease. Here, ERBB2 is linked to breast cancer.